TRT and the Prostate
From Huggins-Era Fear to the Saturation Model and TRAVERSE
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Testosterone labels historically warned on prostate; 2025-2026 FDA review narrowed prostate-cancer language toward metastatic disease only
Reference only. Not medical advice.
What can go wrong
Active metastatic/advanced prostate cancer remains a setting where testosterone is contraindicated, and the saturation model does not claim testosterone is irrelevant to the prostate, only that it saturates at low levels. PSA surveillance is still advised because testosterone can unmask a pre-existing occult cancer by raising PSA into a detectable range, and the long-term data in men with treated localized cancer on active surveillance, while increasingly reassuring, are not definitive. Some critics argue the saturation model is over-applied beyond its evidence.
This is something to take to a clinician. The Atlas can tell you what is known about trt and the prostate in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
The fear that testosterone fuels prostate cancer dates to Huggins and Hodges' 1941 Nobel-winning work showing that castration shrank metastatic prostate cancer and testosterone could flare it. Abraham Morgentaler's saturation model (Eur Urol 2009) reframed this: prostate androgen receptors are saturated at relatively low testosterone concentrations (clinical data suggest a threshold around 250 ng/dL), so raising testosterone from low to normal adds little further androgenic stimulus. Modern data, including the TRAVERSE trial (2023) and multiple meta-analyses, have not shown that TRT increases prostate-cancer incidence at replacement levels. In June 2026 the FDA requested narrowing the prostate-cancer contraindication toward metastatic disease, while preserving PSA surveillance.
For 80 years doctors feared testosterone fed prostate cancer; the saturation model and modern data largely upended that fear.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Prostate growth is androgen-dependent at low androgen concentrations, but the androgen receptor and downstream growth signaling become saturated once testosterone reaches a modest threshold. Below saturation (e.g., castrate range), small changes in androgen markedly change prostate behavior, which is why castration treats advanced disease and why testosterone can flare castrate-range tumors. Above saturation, adding more testosterone produces little additional androgenic effect on prostate tissue, which is the mechanistic basis for why moving a hypogonadal man into the normal range does not appear to behave like 'feeding' cancer.
Safety in detail
This intervention involves significant physiological effects and requires evaluation and monitoring by a qualified physician. Self-administration without medical oversight carries documented health risks. Testosterone is contraindicated in active metastatic prostate cancer; PSA surveillance is standard.
What it does to fertility
Prostate considerations are independent of fertility; the fertility impact of TRT is governed by HPG-axis suppression, addressed separately with hCG/SERM strategies.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Baseline PSA and prostate exam
- PSA reassessment after initiation (e.g., 3-12 months) and per screening guidelines
- Urology referral for significant PSA change or abnormal exam
- Shared decision-making in men with prostate-cancer history
What people get wrong
Often saidTestosterone causes prostate cancer
ActuallyModern RCT and meta-analytic data do not show that replacement-dose testosterone increases prostate-cancer incidence; the historical fear rested on castrate-range physiology and very small early datasets.
Often saidA man with any prostate cancer history can never have TRT
ActuallyActive metastatic disease is the clear contraindication; TRT in treated localized disease and on active surveillance is increasingly used with surveillance, though data are not definitive.
Often saidThe saturation model proves testosterone is completely safe for the prostate
ActuallyIt explains why raising T from low to normal adds little stimulus, but it is a model, not a guarantee; PSA monitoring and individualized judgment remain standard.
Who profits, and who pushes back
Critics of broad saturation-model application
The saturation model is well-supported below threshold but should not be stretched into a blanket safety claim for all prostate-cancer settings.
How we got here
Huggins and Hodges showed in 1941 that androgen deprivation regressed metastatic prostate cancer, work that won the 1966 Nobel Prize and established the dogma that androgens drive prostate cancer. For decades clinicians extrapolated this to mean any testosterone was dangerous to the prostate, and testosterone was withheld from hypogonadal men with any prostate history. Morgentaler challenged this in the 2000s, arguing the original data rested on very few patients and that the saturation model better explained the observations; he and others compiled series of TRT in men with treated and even untreated prostate cancer without the predicted catastrophe. TRAVERSE and large meta-analyses then supplied prospective data, and by 2025-2026 the FDA moved to narrow the prostate-cancer labeling.
- 1941Huggins & Hodges link androgen deprivation to prostate-cancer regression
- 1966Huggins awarded the Nobel Prize
- 2009Morgentaler & Traish formalize the saturation model (Eur Urol)
- 2018Endocrine Society and AUA guidelines codify PSA surveillance rather than blanket avoidance
- 2023TRAVERSE: no signal of increased prostate cancer at replacement levels
- 2026FDA requests narrowing prostate-cancer label toward metastatic disease
What we do not know
- Long-term prostate outcomes of TRT in men on active surveillance
- Whether any subgroup sees increased aggressive-cancer risk
- Where exactly the saturation threshold sits and how it varies
At a glance
- Origin of the fear
- Huggins & Hodges 1941: castration regresses metastatic prostate cancer
- Saturation model
- Morgentaler 2009: AR saturates ~250 ng/dL; more T adds little prostate stimulus
- Modern incidence data
- TRAVERSE and meta-analyses: no clear increase at replacement levels
- Absolute contraindication
- Active metastatic/advanced prostate cancer
- 2026 FDA action
- Requested narrowing prostate-cancer label toward metastatic disease only
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about TRT and the Prostate. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Morgentaler & Traish saturation model (Eur Urol)2009
Proposed androgen-receptor saturation at low testosterone as the explanation for the limited androgen-dependence of prostate growth above threshold
TRAVERSE (Lincoff et al., NEJM)2023
No clear increase in prostate-cancer incidence with testosterone vs placebo over the trial period
Multiple meta-analyses of RCTs2016-2026
Pooled data have not shown a consistent increase in prostate-cancer risk with replacement-dose testosterone